Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

About this trial

The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients able to understand and sign the informed consent form.

Documented HIV-1 infection.

Under the first line TLD for at least 6 months.

At least 3 months follow-up with CV >200c/ml.

Disqualifiers

Patients <18 years of age.

Under the first line regime other than TLD.

Patients with active neoplastic processes.

Patients with active opportunistic diseases.

Trial population

HIV-1 infected men or women \>18 years controlled in the day care center of Chokwé Hospital

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Not applicable- observational study

    Other intervention

    Not applicable- observational study

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: HIV-1 infected men or women >18 years controlled in the day care center of Chokwé Hospital1 intervention

Trial outcomes

Primary outcomes

1

Selection of DRM to dolutegravir and/or tenofovir and/or lamivudine

% of Selection of DRM to dolutegravir and/or tenofovir and/or lamivudine

Time frame
3 months

Secondary outcomes

Other outcomes